派格生物医药-B（02565）今日盘中大跌5.02%，延续了其港股上市首日的颓势。该公司昨日在港交所正式挂牌上市，但首日股价就出现大幅下跌。
根据消息，派格生物医药昨日在港交所上市，发行价为15.6港元/股。然而，上市首日股价就大跌25.9%，收盘价为11.66港元/股，市值缩水至约32.55亿港元。这种破发现象反映了投资者对该公司当前估值和未来前景的担忧。
派格生物医药成立于2008年，专注于自主研究及开发慢性病创新疗法，重点关注内分泌代谢领域。目前，公司有6款候选产品，但尚未有商业化产品。其中，进展最快的是一款GLP-1激动剂PB-119，其针对糖尿病的单药和联合疗法已提交上市注册申请。分析认为，公司股价持续下跌可能与其尚未盈利且产品未商业化有关。不过，核心产品PB-119前景被认为较好，如果获批上市，有望改善公司业绩，扭转市场对其估值预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.